This marks a significant step forward in the multi-regional partnership between Deciphera and Medison
ZUG, Switzerland and TORONTO, Sept. 29, 2023 /CNW/ -- Today, Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, is pleased to announce the public formulary listing of QINLOCK® in Canadian provinces: Ontario and Quebec. These provinces join Alberta, Saskatchewan, Manitoba, and the Non-Insured Health Benefits (NIHB) program, further broadening the public formulary coverage for adult patients with advanced gastrointestinal stromal tumor (GIST) who have previously been treated with imatinib, sunitinib, and regorafenib.
Read more at newswire.ca
/Pfizer%20Inc_%20logo%20sign-by%20JHVEPhoto%20via%20iStock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
